Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up Safety Study of Selexipag
2020-000475-21Phase 3Active
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of selexipag in pulmonary hypertension (PH), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Frequency of adverse events. Started May 2022; status: active.
02
Drugs
selexipag
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on 2020-000475-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000475-21.